angina, stroke, post-stroke, heart failure and death. It has an annual cycle and estimates mean quality-adjusted survival and treatment cost, which reflects hypertension treatment and the management of cardiovascular events. Risk functions were used to conduct extrapolations. Data on treatment effectiveness, quality-of-life and epidemiology were obtained from published clinical trials and studies. The database of the main insurance fund (IKA) was analysed to estimate the cost of events. The analysis was done from a payer perspective, all outcomes were discounted at 3% and prices correspond to 2008. RESULTS: The estimated patient cost per annum for each health state was: stable angina: €2232; unstable angina: €2572; myocardial infarction: €2473; post-MI: €1677; stroke: €12,233; post-stroke: €1240; heart failure: €2655; angiogram: €1544; angioplasty: €6511; bypass surgery; €11,514. For the baseline group (age: 57 years, systolic-blood-pressure: 147, cholesterol: 6.00 mmol/L, BMI: 29 kg/m^2) with mild/moderate disease, the total cost was €1,146 with irbesartan, €15,486 with losartan and €15,613 valsartan; QALYs were 12.67, 12.63 and 12.64, respectively. For the group with severe disease, the total cost with irbesartan was €15,798 (150 mg) and €18,697 (300 mg), whilst with Losartan was €16,295 (50 mg) and €22,496 (100 mg); QALYs were 12.47 and 12.37 for irbesartan and losartan respectively. Thus, irbesartan was less costly and more effective and dominated the other two treatments. Similar results were obtained in relation to various other patient groups and several sensitivity analyses. CONCLUSIONS: For different patient populations, irbesartan represents good value for money in the Greek NHS setting, compared to selected commonly used alternatives.

AN ECONOMIC EVALUATION OF THE ADDITION OF FIXED-DOSE NIAIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY IN TERMS OF OPTIMAL LIPID VALUE ATTAINMENT

Balu S1, Simko RJ1, Burge RT1, Cziraky MJ2, Quimbo RA2
1Abbott Labs, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA

OBJECTIVES: To model the impact of the addition of fixed-dose niacin extended-release and simvastatin (NER/S) therapy to a health plan formulary in terms of optimal low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglyceride (TG) value attainment. METHODS: Two hypothetical formularies with all major branded and generic lipid drugs were modeled over a three year time horizon: a formulary not including NER/S (current formulary) and a formulary which did (revised formulary). Primary and secondary risk patients with ≥1 sub-optimal lipid parameter were sampled from the HealthCore Integrated Research Database between 1/1/2000 and 2/28/2005. Package insert efficacy of antihyperlipidemic medications in each formulary was applied to the sample population. Post-treatment lipid values were evaluated according to U.S. lipid guidelines. Rates of individual and combined optimal lipid value (OLV) [LDL-C, HDL-C, and TG] achievement were estimated in direct proportion to lipid therapy market shares in both formularies. Changes in clinical outcomes between formularies were evaluated relative to incremental change in pharmacy and cardiovascular (CV) disease related medical costs. Market penetration of NER/S was assumed to be 1.5% and payer discounts of 17% and 50% were applied to branded and generic wholesale acquisition costs. RESULTS: The rate of combined OLV attainment over three years in the revised formulary increased 0.57% from the current formulary. Attainment of optimal LDL-C, HDL-C and TG values increased by 0.07%, 0.30%, and 0.10%, respectively. The cost for a 1% increase in optimal LDL-C, HDL-C, and TG attainment was $3103, $952, and $2047 respectively. There was an estimated $1147 cost for every 1% increase in combined OLV attainment. CONCLUSIONS: The addition of NERS to the health plan formulary increases individual and combined OLV achievement thereby having the potential to reduce the incidence of CV events and CV-related medical costs.

CHANGE IN LIPID VALUES, TARGET LIPID VALUE ATTAINMENT, AND ANNUAL HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS INITIATING COMBINATION STATIN AND EXTENDED-RELEASE NIACIN THERAPY

Simko RJ1, Burge RT1, Balu S1, Tunceli O2, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA

OBJECTIVES: To evaluate changes in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-
C), and triglyceride (TG) goal attainment, annual cardiovascular disease (CVD)-related health care utilization and costs among patients initiating combination statin and extended-release niacin (NER) therapy (S + NER + S). METHODS: A retrospective cohort study of patients initiating S + ERN between January 1, 2000 and June 30, 2006 was conducted utilizing medical, pharmacy and laboratory result data from the HealthCore Integrated Research Database. Patients were primary or secondary risk, aged ≥18 years, had ≥1 laboratory test result within 12 months prior to index date, and ≥12 months pre- and post-index eligibility. Clinical and economic outcomes were evaluated during the 12 months prior to and after initiation of S + ERN. Lipid goal attainment was determined based on US national lipid guidelines. CVD-related resource utilization and costs were annualized post-index. Change in lipid goal attainment, annual resource utilization and costs were tested using Generalized Estimating Equations (GEE). Model covariates for lipid goal attainment included age, gender, time to NER addition, and co-morbidity index. RESULTS: A total of 764 (51% secondary risk) patients initiating NER + S were identified. Patients were predominantly male (77%), mean age 52.6 (±9.05) years and time to achievement of NER was 225 (±306) days. Mean change in lipid values (mg/dL) for LDL-C, HDL-C, and TG was (−10.81 ± 30.67, 2.73 ± 7.24, and −22.67 ± 106.79) respectively. Multivariate analysis demonstrated increased likelihood of goal attainment for LDL-C (OR: 1.56; p = 0.0001), HDL-C (OR: 1.58; p = 0.0004), and TG (OR: 1.39; p = 0.0078) after initiation of NER + S therapy. GEE results demonstrated significant improvement from pre-index in annual CVD attributable inpatient visits (17 ± 49 vs 9 ± 31 per 100 patients; p < 0.0001) and total medical cost ($3214 ± 10,282 vs. $2039 ± 7117; p < 0.0001). CONCLUSIONS: Comprehensive treatment approach of combination NER + S therapy was associated with improved change in lipid values, target lipid value attainment, and reduced CVD-related inpatient visits and total medical cost.

PCV83

AN EVALUATION OF THE INCREMENTAL CHANGE IN THE INCIDENCE OF CARDIOVASCULAR EVENTS AND RELATED COSTS WITH THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY

Balu S1, Simko RJ2, Burge RT3, Cziraky MJ3, Quimbo RA3
1Abbott Labs, Abbott Park, IL, USA, 2Abbott Laboratories, Abbott Park, IL, USA, 3HealthCore, Inc, Wilmington, DE, USA

OBJECTIVES: To model the impact of the addition of fixed-dose niacin extended-release and simvastatin (NER/S) therapy to a health plan formulary in terms of cardiovascular (CV) events and corresponding attributable costs. METHODS: Two hypothetical formularies with all major branded and generic lipid drugs were modeled over a three year time horizon: a formulary not including NER/S (current formulary) and a formulary which did (revised formulary). Primary and secondary risk patients with ≥1 sub-optimal lipid parameter were sampled from the HealthCore Integrated Research Database between 1/1/2000 and 2/28/2005. Package insert efficacy of antihyperlipidemic medications in each formulary was applied to the sample population. Changes in clinical outcomes (combined lipid value attainment of low density lipoprotein cholesterol, high density lipoprotein cholesterol, and triglycerides, and CV events) between formularies were evaluated relative to incremental change in pharmacy and CV disease-related medical costs. Market penetration of NER/S was assumed to be 1.5% and payer discounts of 17% and 50% were applied to brand and generic wholesale acquisition costs. RESULTS: For every 1% increase in NER/S market share there was a corresponding 0.38% increase in the incremental rate of combined OLV achievement and 0.06% decrease in the incremental incidence of CV events between current and revised formularies. Total health system drug expenditure increased by 15% while CV event costs decreased by 10%. The incremental cost per CV event avoided was $46,593 and $12,957 per CV event related hospital day avoided. CONCLUSIONS: The addition of NER/S to the health plan formulary increases combined optimal lipid value achievement and correspondingly reduces the three year incidence of CV events and CV event related costs in this hypothetical patient population.

PCV84

HEALTH CARE RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007: FRENCH BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)

Ferrieres J1, Therny-Lessensot S2, Sartral M3, Pantel JF4, Delahais V5
1CHU Rangueil, Toulouse, France, 2Lilly France, Suresnes, France, 3Ef Lilly and Company Ltd, Sureignes, France

OBJECTIVES: This analysis aims to explore management of acute coronary syndromes (ACS) from acute event to hospital discharge in France. METHODS: This 12-month prospective, observational study recruited ACS patients undergoing percutaneous coronary intervention (PCI), January-August 2007, capturing practice patterns, resource use and quality of life. In France, all interventional cardiologists were invited to participate. RESULTS: 497 ACS-PCI patients (483 analyzed), enrolled by 59 interventional cardiologists from public universities-36%, public non-university hospitals-45%, and private hospitals-19%, were: mean age 60.9 ± 12.8, mean weight 79.7 kg ± 14.8, 18% female, 16% diabetics and 12% prior myocardial infarction (MI). Index diagnosis was: unstable angina or non-ST-elevation MI (UA/NSTEMI)-53% and ST-elevation MI (STEMI)-47%. Almost all patients (96%) were implanted stents: 67% bare metal stents (BMS), 23% drug eluting stents (DES) and 11% both. Antiplatelet loading oral medications used were aspirin-91% and clopidogrel-95% (no use of ticlopidine). Antithrombotic agents were infused too: abciximab-16%, tirofiban-18%, eptifibatide-3%, and bivalirudin-3%. Clopidogrel loading dose (LD) was given in intensive care unit-32%, emergency room-24%, ambulance-21%, previous hospital-12%, catheter lab-6% and other ward-4%, and close to PCI (previous 6 hours, during or after) in 46% of cases. Total clopidogrel loading dose was over 300 mg in 34% of cases, and in-hospital maintenance dose (MD) was 150 mg in 26%, and 75 mg in 74% of cases. At time of hospital discharge, 96% of patients were receiving clopidogrel (discharge dose 150 mg in 23%) and EQ-5D QoL score was a median 0.85 (IQR 0.73–1.00). CONCLUSIONS: These data reflect contemporary real-life management of ACS patients in France. DES are implanted 3 times less than BMS. Variation in oral antiplatelet agent dosing pattern (LD and MD) and timing of administration is frequent.

PCV85

STROKE PATIENT RESOURCE USE AND CAREGIVER BURDEN OUTCOMES BY SEVERITY (RECOVERY) STUDY: METHODS AND RESULTS FROM THE ATHENS STROKE REGISTRY

Payne K1, Carson JJ2, Lordan N3, Huybrechts KP4, Ishak KJ5, Rylander A6, Vennos K7
1United BioSource Corporation, Montreal, QC, Canada, 2United BioSource Corporation, Concord, MA, USA, 3AstraZeneca Sweden AB, Sodertalje, Sweden, 4University of Athens School of Medicine; Alexandra Hospital, Athens, Greece

OBJECTIVES: To collect location of care, resource utilization, utilities and quality of life data in relation to post-stroke physical